8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2005

IMCLONE SYSTEMS INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware	0-19612	04-2834797
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

180 Varick Street

New York, New York 10014

(Address of principal executive offices) (Zip Code)

(212) 645-1405

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

On July 26, 2005, ImClone Systems Incorporated issued a press release, attached as Exhibit 99.1 and incorporated herein by reference, announcing that it is scheduled to present at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference in Southampton, New York, on Thursday, July 28, 2005, from 8:45 AM to 9:25 AM Eastern Daylight Time.

The press release is being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities under that Section.  Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of ImClone Systems Incorporated under the Securities Act of 1933.

Item 9.01  Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press Release of ImClone Systems Incorporated, dated July 26, 2005.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMCLONE SYSTEMS INCORPORATED (Registrant)
Dated July 26, 2005	By:	/s/ Erik D. Ramanathan
			Erik D. Ramanathan
			Vice President and General Counsel

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of ImClone Systems Incorporated, dated July 26, 2005.

4

EX-99.1

Exhibit 99.1

ImClone Systems
Incorporated
	180 Varick Street
	New York, NY 10014
	Tel:	(212) 645-1405 (212) 645-2054
	Fax:
	www.imclone.com

ImClone Systems Incorporated

Investors:

Andrea F. Rabney

(646) 638-5058

Stefania Bethlen

(646) 638-5058

NOT FOR IMMEDIATE RELEASE

IMCLONE SYSTEMS TO PRESENT AT THE

BANC OF AMERICA SECURITIES

2005 SPECIALTY PHARMACEUTICALS CONFERENCE

New York, NY – July 26, 2005 – ImClone Systems Incorporated (NASDAQ: IMCL) announced today that Michael J. Howerton, Chief Financial Officer, is scheduled to present at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference in Southampton, NY on Thursday, July 28, 2005, from 8:45 AM to 9:25 AM Eastern Daylight Time.  Mr. Howerton will provide a corporate overview, including comments on the Company’s product portfolio.

The presentation will be webcast live and may be accessed by visiting ImClone Systems’ website at www.imclone.com. A replay of the webcast will also be available immediately after the conclusion of the presentation.  Investors can access the webcast under “Presentations” in the “Investor Relations” section of ImClone Systems’ website.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.  The Company’s research and development programs include growth factor blockers and angiogenesis inhibitors.   ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market.  ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the company believes that the expectations reflected in

such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved.  Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the company’s ability to control or predict.  Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K.  For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

#  #  #